<DOC>
	<DOCNO>NCT02584660</DOCNO>
	<brief_summary>The purpose study evaluate low risk Pulmonary Embolism ( PE ) participant discharge Emergency Department ( ED ) home environment treat rivaroxaban outpatient few total day hospital bleed and/or venous thromboembolism ( VTE ) event Day 30 compare participant treat initial hospitalization standard-of-care .</brief_summary>
	<brief_title>A Study Rivaroxaban Early Discharge Low Risk Pulmonary Embolism From Emergency Department</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , open-label ( people know identity intervention ) , parallel-group , multicenter ( study conduct multiple site ) study evaluate low risk PE participant discharge ED treat rivaroxaban compare participant treat initial hospitalization standard-of-care . The study consist Screening Randomization Period , follow 90-day open-label treatment period , end study/early withdrawal ( EOS ) visit . The duration study participation participant approximately 3 month . The participant randomize 1:1 ratio one two treatment . Safety monitor study .</detailed_description>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Have confirm acute symptomatic Pulmonary Embolism ( PE ) without symptomatic deep vein thrombosis ( DVT ) A PE participant diagnose Emergency Department ( ED ) deem low risk clinical deterioration determine Hestia criterion Have contraindication able complete randomize treatment study assessment Have life expectancy least 6 month Must willing able adhere prohibition restriction specify protocol Having receive Combined Pgp ( Pglycoprotein ) strong CYP3A4 ( Cytochrome P450 ) inhibitor ( limited ketoconazole , telithromycin protease inhibitor ) use within 4 day randomization , plan use study . Itraconazole use within 7 day randomization plan use study Having receive Combined Pgp strong CYP3A4 inducer ( limited rifampin/rifampicin , rifabutin , rifapentine , phenytoin , phenobarbital , carbamazepine , St. John 's Wort ) use within 2 week randomization plan use study Who Has contraindication use anticoagulant therapy ( example , bleed diathesis , history gastrointestinal bleeding within 1 year coagulopathy document Screening ) Who Has know allergy , hypersensitivity , intolerance rivaroxaban excipients Woman pregnant , breastfeeding , plan become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Rivaroxaban</keyword>
	<keyword>JNJ39039039</keyword>
	<keyword>Pulmonary embolism</keyword>
</DOC>